



# Duplications of the critical Rubinstein—Taybi deletion region on chromosome 16p13.3 cause a novel recognisable syndrome

Bernard Thienpont,<sup>1</sup> Frédérique Béna,<sup>2</sup> Jeroen Breckpot,<sup>1</sup> Nicole Philip,<sup>3</sup> Björn Menten,<sup>4</sup> Hilde Van Esch,<sup>1</sup> Emmanuel Scalais,<sup>5</sup> Jessica M Salamone,<sup>6</sup> Chin-To Fong,<sup>6</sup> Jennifer L Kussmann,<sup>7</sup> Dorothy K Grange,<sup>8</sup> Jerome L Gorski,<sup>7</sup> Farah Zahir,<sup>9</sup> Siu Li Yong,<sup>10</sup> Michael M Morris,<sup>2</sup> Stefania Gimelli,<sup>2</sup> Jean-Pierre Fryns,<sup>1</sup> Geert Mortier,<sup>4</sup> Jan M Friedman,<sup>9</sup> Laurent Villard,<sup>11</sup> Armand Bottani,<sup>2</sup> Joris R Vermeesch,<sup>1</sup> Sau Wai Cheung,<sup>12</sup> Koen Devriendt<sup>1</sup>

For numbered affiliations see end of article

## Correspondence to

Professor Dr Koen Devriendt, Center for Human Genetics, K.U. Leuven, Herestraat 49 box 602, Leuven 3000, Belgium; koenraad.devriendt@uzleuven.be

Received 24 June 2009

Accepted 19 July 2009

## ABSTRACT

**Background** The introduction of molecular karyotyping technologies facilitated the identification of specific genetic disorders associated with imbalances of certain genomic regions. A detailed phenotypic delineation of interstitial 16p13.3 duplications is hampered by the scarcity of such patients.

**Objectives** To delineate the phenotypic spectrum associated with interstitial 16p13.3 duplications, and perform a genotype-phenotype analysis.

**Results** The present report describes the genotypic and phenotypic delineation of nine submicroscopic interstitial 16p13.3 duplications. The critically duplicated region encompasses a single gene, *CREBBP*, which is mutated or deleted in Rubinstein—Taybi syndrome. In 10 out of the 12 hitherto described probands, the duplication arose de novo.

**Conclusions** Interstitial 16p13.3 duplications have a recognizable phenotype, characterized by normal to moderately retarded mental development, normal growth, mild arthrogryposis, frequently small and proximally implanted thumbs and characteristic facial features. Occasionally, developmental defects of the heart, genitalia, palate or the eyes are observed. The frequent de novo occurrence of 16p13.3 duplications demonstrates the reduced reproductive fitness associated with this genotype. Inheritance of the duplication from a clinically normal parent in two cases indicates that the associated phenotype is incompletely penetrant.

## INTRODUCTION

Chromosomal imbalances are a cause of genetic disorders and often cause a syndromic phenotype. The identification of such imbalances on a genome-wide level was until recently only feasible by investigating metaphase chromosomes under a microscope. The latest developments in microarray technology, however, enable assessment of copy number of thousands to millions of loci across the human genome at a resolution far surpassing that of conventional karyotyping. The introduction of these technologies into the diagnostic work-up of patients with congenital disorders represents a revolution in this field, the importance of which cannot be overstated. It led to a vast improvement in the aetio-

logical diagnosis of patients with previously idiopathic congenital abnormalities, mental retardation (MR) and/or psychiatric problems.<sup>1</sup> It moreover permitted the identification and delineation of novel microdeletion and microduplication syndromes, thus allowing a more detailed assessment of the phenotypic consequences associated with specific chromosomal imbalances and more accurate and targeted care and counselling of patients and their parents.<sup>2</sup> The present study describes the identification and delineation of a novel microduplication syndrome, microduplication 16p13.3, which is complementary to microdeletions of 16p13.3 that cause Rubinstein—Taybi syndrome (RTS).<sup>3</sup>

## PATIENTS, MATERIALS AND METHODS

Patients described in this study were referred for idiopathic MR and/or congenital anomalies. They were followed in the collaborating centres, and clinical data and informed consent were obtained from all patients or their legal representatives. A genome-wide copy number profile of the patient DNA was obtained by subjecting it to microarray analysis using the Affymetrix 500K GeneChip platform (patient 2), the genome-wide 105K V7 OLIGO array (a custom designed array manufactured by Agilent Technologies Inc (Santa Clara, California, USA), containing oligonucleotides as probes chosen genome-wide with an average interval of 30 kb plus an enrichment of probes in most known regions associated with syndromes, pericentromeric and subtelomeric regions) (patients 1, 3, 6 and 8), the Agilent 244K platform (patients 7, 9 and 11) or the Agilent 44K platform (patient 12), all according to manufacturers' recommendations, or using a tiling resolution bacterial artificial chromosome (BAC) array of chromosome 16 (patient 4) as described.<sup>4</sup> The duplication in patient 9 was first detected by a microdeletion multiplex ligation dependent probe amplification (MLPA) kit (MRC Holland, Salsa MLPA P245) (Amsterdam, the Netherlands). All genome coordinates mentioned in this study are according to human genome build 18 (NCBI 36.1). The inheritance of each of these duplications was investigated by analysing parental samples using microarrays (patient 2) or targeted approaches such as fluorescent in situ hybridisation

(FISH) (patients 1, 3, 4, 6, and 8), MLPA (patients 9 and 11) or quantitative polymerase chain reaction (PCR) (patients 7 and 12). Positions of segmental duplications were downloaded from the segmental duplication database website (<http://humanparalogy.gs.washington.edu/build36/>). The duplications in patients 2, 5 and 10 were previously reported.<sup>5–7</sup>

## RESULTS

Nine patients with an interstitial duplication of 16p13.3 are described for the first time in the present study. Of the three previously reported patients (patients 2, 5 and 10),<sup>5–7</sup> we have added more accurate genotypic and phenotypic data for patient 2. The results from micro-array analyses for patients 1–4, 6–9 and 11–12 are depicted in figure 1 together with the reported results from investigations in patients 5 and 10. The molecular data are summarised in table 1. The duplication occurred de novo in 10 cases and was inherited from a clinically normal parent in two cases (patient 3 (maternal) and patient 8 (paternal)).

Comparing the extent of all duplicated regions enabled the delineation of a critically duplicated region, which contains a single gene: *CREBBP* (figure 1). We also reanalysed the molecular karyotype of the patient reported to have an interstitial 16p13.3 duplication by de Ravel,<sup>8</sup> using a higher resolution platform (Agilent 244K). This revealed that the duplication described in this patient was not interstitial but terminal, extending from 0 kb to 8633–8648 kb, and is 2–10 times larger than the interstitial duplications in patients 1–12. This patient was, therefore, not included in the present analysis.

There was no family history of birth defects except for patient 2, whose father had one brother with a congenital heart defect who died at 8 months of age and one sister with a history of cardiac arrhythmias, and patient 3, where both parents had heart murmurs at birth that resolved spontaneously after a few years.


Phenotypically, interstitial duplications of 16p13.3 are associated with variable mental development (ranging from normal to moderately delayed), and occasional behavioural problems such as attention deficit hyperactivity disorders, aggressive behaviour, and autism spectrum disorders. Pregnancy was uncomplicated in most; the mother of patient 3 had one abnormal non-stress test and mild oligohydramnios was noted, and patient 12 had intrauterine growth retardation. There was

no exposure to alcohol or other known teratogens except in patient 3, where the mother reported occasional alcohol consumption in the first weeks of pregnancy. Birth was at term in all patients. Growth was normal in all individuals except patient 12 who had precocious puberty.

Many patients shared similar facial features. There was midfacial hypoplasia in young children and a longer face in older individuals. The nose was prominent and had a bulbous tip, and the eyes were often upslanting with narrow palpebral fissures, sometimes with ptosis. The upper lip typically was thin, and the ears low set and/or protruding (figure 2). We frequently observed mild abnormalities of the hands (the thumbs were often proximally implanted and short, fingers were long and tapering, the fifth finger was often short, there was also often camptodactyly or mild cutaneous syndactyly) and of the feet (club feet, camptodactyly, or syndactyly) (figure 2). Less frequent were other anomalies of the skeleton (congenital hip dislocation, vertebral fusion), the eyes (blepharophimosis, epicanthus inversus, strabismus, astigmatism, or ptosis), and the heart (atrial septal defect, tetralogy of Fallot). Occasional findings include inguinal hernia (twice), precocious puberty, cryptorchidism (twice), submucosal cleft palate, and mild periventricular heterotopia on magnetic resonance imaging (MRI) examination of the brain. An overview of the phenotypic data of the individual patients is given in table 1. The frequent occurrence of features such as club feet, camptodactyly of the toes and fingers, congenital hip dislocation, and incomplete extension of the elbows is indicative of mild arthrogryposis in these patients.

A total of about 25 700 patients have been analysed for duplication of the *CREBBP* gene in our centres. In this patient population, 11 duplications of *CREBBP* were found, suggesting a frequency of this duplication of around 0.043% in these patients. As about 2–3% of live births fit the inclusion criteria for our patient cohort (multiple congenital anomaly/mental retardation (MCA/MR)) and about 80% of these are idiopathic before molecular karyotyping,<sup>9</sup> we estimate the frequency of this duplication to be 1 in 97 000 to 146 000 live births.

Three different mechanisms have been proposed to generate chromosome imbalances: non-allelic homologous recombination (NAHR), non-homologous end joining, and fork stalling and template switching (FoStEs).<sup>10</sup> When a region is recurrently



**Figure 1** Upper panel: the extent of the duplications identified in the present study. Light grey bars indicate normal copy number, black bars indicate duplicated regions, dark grey bars indicate the breakpoint containing regions. Patients are ordered according to the telomeric breakpoint of the duplication. Lower panel: a view of the University of California Santa Cruz (UCSC) genome browser (NCBI build 36.1, March 2006), illustrating the genes mapped to the implicated region (first track), the regions that are copy number variable in the normal population (Database of Genomic Variants, second track), and the regions that have paralogues in the human genome (Segmental duplication – Seg Dup; third track). The transparent grey box demarcates the smallest region of overlap. All breakpoints appear unique and do not map specifically in low copy repeats.

**Table 1** Genotypic and phenotypic characteristics of patients with an interstitial 16p13.3 duplication

Patient	1	2	3	4	5	6	7	8	9	10	11	12
Telom bcr (kb)	1863–1880	2680–2682	2812–2813	2937–3083	2978–3292	2998–3032	3506–3513	3513–3542	3597–3604	3629–3648	3651–3656	3667–3688
Centrom bcr (kb)	4665–4693	3874–3927	4765–5365	5706–5847	4851–5074	4328–4367	6165–6177	4736–4758	3942–3953	3993–4109	4281–4290	4574–4599
Inheritance	De novo	De novo	Maternal	De novo	De novo	De novo	De novo	Paternal	De novo	De novo	De novo	De novo
Gender	Female	Male	Male	Male	Female	Male	Male	Female	Female	Male	Female	Male
Biometry W	p50	p50	p50	p5	p10	p50	p50	p10–25	p3	p25	p10	—
At birth L	p50	—	<p5	—	p75	—	p25	p5–10	<p3	p25–50	p10	p90
OFC	—	—	p50–75	—	p25	—	p75	p25	—	p50–75	p50	—
Age last consult	4½ months	13 y 6 months	3 Y	11 Y	16 Y	8 Y	18 Y	3 Y	8 Y	15 Y	2 y 9 months	10 Y
Growth	Normal H p10; W p25; OFC p10 W p75–90; OFC p90	Normal W, p3; H p50, OFC p 10	Normal Wp25–50; H p10; OFC p3	Normal W, p3; H p50, OFC p 10	Normal	Normal	Normal W p25–50; H p75–97; OFC p25–50	Normal W p25; H p90	Normal W p10; H p10–25	Normal W, L and OFC at p75	Normal W and H p25–p50; OFC p50–p75	Normal W and H Precocious puberty (W > p97, H > p97, OFC p40)
Delay in development	—	Mod (WISC-III IQ 46); pronounced speech delay	Mild (LPS-R; brief IQ 68—fluid IQ 51—perf: 52; verb: 54)	Mod (WISC-R; IQ 51—perf: 52; verb: 54)	Mod (WISC-R IQ 45 perf 63; verb 39) severe verbal dyspraxia	Mod (WISC IQ 50)	Mild-mod (IQ 56); speech articulation problems	Mild (PLS-4; expressive language 74; total 77)	Low normal intelligence; speech articulation defect	Mod	Mild	Low normal intelligence
Behaviour	—	No behavioural problems	No behavioural problems	Behavioural problems	No behavioural problems	AuD; ADHD	AuD; ADHD; aggressive	No behavioural problems	No behavioural problems	—	No behavioural problems	No behavioural problems
Hands	Short, proximally implanted, adducted thumbs	Short fifth fingers	Hypoplastic thumbs and thenar eminences; long fingers	Short, proximally implanted thumbs; II-V	Tapering fingers; short fifth finger	Camptodactyly 2–5	Short fingers	Tapering long fingers	Proximally implanted thumbs; long fingers; long hyperconvex nails	Mild cutaneous syndactyly, camptodactyly (fingers 2–4)	Small, proximally implanted and adducted thumbs	Large, proximally implanted thumbs; mild syndactyly 2–3, camptodactyly (2, 3 and 4)
Feet	Vertical talus; dorsiflexion; proximally placed toes I	Pes cavus; camptodactyly; 4–5 clinodactyly	Medially deviating, broad toes; abnormal nail beds	Camptodactyly; sandal gap	Bilateral equinovalgus; short toes; camptodactyly; sandal gap	Camptodactyly 2–4	Sandal gap; camptodactyly; sandal gap	Mild 2–3 syndactyly; club foot right	Dysplastic toe nails; camptodactyly; hallux valgus	—	Short halluces	Large halluces; sandal gap
Musculoskeletal findings	—	C5–C6 vertebral fusion; mild pectus excavatum	Plagiocephaly; leg length discrepancy; normal joint mobility	Mild pectus excavatum; flat, asymmetric thorax	—	—	Scoliosis	Hip dislocation; spinal lipoma	Severe congenital left hip luxation	Incomplete extension elbows	—	—
Eyes	—	Blepharophimosis; bilateral ptosis; epicanthus inversus	Bilateral ptosis, esotropia	Ptosis left eye, eye motility disturbance	—	—	Deep set	Normal	—	—	Strabismus	Normal
Heart	ASD-I; VSD; leaky AV valves	Normal	ToF	Normal	—	ASD	Normal (VSD spontaneously closed)	Normal	Normal	ASD type II	Normal	—
Dysmorphism	Bitemporal narrowing; short upslanting palpebral fissures; left preauricular tag; lacrimal duct obstruction	Low set, mildly dysplastic ears; overtumed helices of the ears; upslanting palpebral fissures; bulbous nose	Sacral dimple; blind uvula; short neck with excess skin; micrognathia; thin upper lip; double hair whorl	Webbed neck; anteverted nares; thin upper lip; mildly protruding ears; epicanthus; long face; pointed chin; narrow palpebral fissures; smooth philtrum	Deep set eyes; small, upslanting palpebral fissures; protruding, abnormal ears; broad nasal bridge; round nasal tip with prominent glabella, long philtrum, midfacial hypoplasia and prominent mandible	Protruding ears; bulbous nose; deep set eyes; deep tented upper lip	Sacral dimple; upslanting palpebral fissures; hypertelorism; synophrys; low set ears; webbed neck; small chin	Midfacial hypoplasia; posteriorly rotated, protruding ears; upslanting palpebral fissures; short nose	Short hypoplastic nose; low set and posteriorly rotated small ears; long flat philtrum; small teeth; facial hypotonia	Mildly protruding ears, broad nose, hirsutism; synophrys; low frontal hair line	Mildly protruding palpebral fissures; large low set ears; low nasal bridge; micrognathia	Smooth philtrum; large mouth; posteriorly rotated, protruding and malformed ears; short nose; upslanting, narrow palpebral fissures

Table 1 Continued

Patient	1	2	3	4	5	6	7	8	9	10	11	12
Other	—	—	Right cryptorchidism; small corpus callosum; EEG normal	Cryptorchidism	Normal MRI and EEG	Inguinal hernia; tracheobroncho- malacia; recurrent respiratory infections; submucous cleft	Inguinal hernia; pyloric stenosis; hypotonia; high palate	Cerebellar angioma; periventricular leucomalacia; thin hair	Permanent drooling	—	Hypotonia; recurrent ear infections	Mild periventricular heterotopia; precocious puberty

Patients 2, 6, 5<sup>7</sup> and 10<sup>5</sup> were reported previously. ASD, autism spectrum disorder; AV, atrioventricular; bcr, breakpoint containing region; EEG, electroencephalogram; H, height; MRI<, magnetic resonance imaging; mod, moderate; ADHD, attention deficit hyperactivity disorder; ASD, atrial septal defect; ASD, autism spectrum disorder; bcr, breakpoint containing region; EEG, electroencephalogram; H, height; MRI<, magnetic resonance imaging; mod, moderate; OFC, occipitofrontal circumference; p, percentile; VSD, ventricular septal defect; W, weight.


found to be deleted as well as duplicated, NAHR has been suggested as a potential underlying mechanism. However, similar to the breakpoints of deletions in this region, all breakpoints of duplications appear unique, arguing against a mechanism of non-allelic homologous recombination. To further exclude a local homology based molecular mechanism, we assessed the presence of segmental duplications (SD; length >10 kb, over 90% homology) in the breakpoint containing regions. SDs encompass 7.7% of the region between 1800–6500 kb, but none of the breakpoints falls clearly within an SD, and only two out of 22 breakpoint containing regions (9%) encompass an SD. We therefore exclude NAHR as the mechanism generating these imbalances. The lack of recurrent breakpoints for the copy number variations in these cases indicates other mechanisms, such as non-homologous end joining or FoSTeS, as possibly causative. There were no complex imbalances identified, a hallmark of the recently proposed FoSTeS mechanism, although the resolution of the analysis was probably insufficient to assess this critically in most cases. None of the parents reported exposure to known mutagens.

## DISCUSSION

The present report details genotype and phenotype of nine patients with an interstitial 16p13.3 duplication. Three patients that were previously reported were also included,<sup>5–7</sup> with more precise genotypic and phenotypic data for one of these (patient 2).<sup>6</sup> Careful assessment of the phenotypic features of these individuals enabled the description of a characteristic phenotype, with normal to moderately retarded mental development, mild arthrogryposis-like anomalies of the musculoskeletal system (club feet, congenital hip dislocation, or camptodactyly of the fingers and toes), mild facial dysmorphism that changes with age and occasional anomalies of the heart (atrial septal defect, tetralogy of Fallot).

It is noteworthy that all patients were selected for study because of MR and/or congenital anomalies. There might thus be—as in most genetic disorders—a bias towards the more severe end of the spectrum in the described phenotype; normal or mildly affected individuals do not present at the genetics clinic. In two instances the duplication was indeed found to be inherited from an apparently normal parent (patients 3 and 8) who had both followed normal schooling, function normally in society, and do not present the typical face. However, the frequent de novo occurrence (in 10 of 12 patients) indicates that this duplication is associated in most cases with a reduced reproductive fitness. In line with this is the finding that *CREBBP* duplications were never identified in genome-wide copy number profiling studies of more than 4000 individuals recruited from normal control populations.<sup>11–13</sup> In the patient populations we studied, we identified an interstitial 16p13.3 duplication in 11 out of 25 700 individuals, suggesting that it occurs in about 0.043% of patients with MR or birth defects.

Three typical patients (9, 10 and 11) carry a very small duplication (maximal sizes 356, 480 and 639 kb), indicating that this is the critical region associated with the described phenotype. This small region encompasses only six genes. Of these genes, *CREBBP* is the most attractive candidate gene. The smallest region of duplication overlap (186–260 kb in size) in the 12 described individuals contains only the *CREBBP* gene. The distally flanking gene, *ADCY9*, is unaffected in patient 2. The proximally flanking gene, *TRAP1*, is only partially duplicated in patient 12, rendering the extra copy probably not functional. *CREBBP* encodes a histone acetyl transferase and thus functions as a transcriptional co-activator by decondensing chromatin and activating gene



**Figure 2** Phenotypic features of patients 1, 2, 4 and 6–12. Please note that patient 2 has had a surgical correction for ptosis.

transcription. Heterozygous loss-of-function mutations and deletions of this gene have been shown to cause RTS,<sup>3 14</sup> demonstrating that human development is sensitive to *CREBBP* dosage.

None of the recurrent phenotypic findings in our patients associate specifically with a region proximal or distal to *CREBBP*

except for ptosis, which was found only in three patients with a more telomerically extending duplication (patients 2–4). In contrast to duplications extending to the subtelomere,<sup>15</sup> interstitial duplications are not associated with microcephaly or growth retardation. Other features reported for terminal

duplications of 16p seem to associate with duplication of *CREBBP*. These include heart defects, MR and the arthrogryposis-like features.<sup>15</sup>

Reciprocal duplications are now being clinically delineated for many of the previously described microdeletion syndromes. Examples include 7q11.23 duplications (reciprocal to Williams–Beuren syndrome deletions),<sup>16</sup> 15q11.2 duplications (reciprocal to Prader–Willi and Angelman syndrome deletions),<sup>17</sup> 17p11.2 duplications (known as Potocki–Lupski syndrome, reciprocal to Smith–Magenis syndrome deletions),<sup>18</sup> 22q11.2 duplications (reciprocal to DiGeorge syndrome deletions),<sup>19</sup> 20 Xq28 duplications (*MECP2* duplications, reciprocal to Rett syndrome deletions)<sup>21</sup> and 17p13.3 duplications (reciprocal to Miller–Dicker syndrome deletions).<sup>22</sup> Some recurrent themes are emerging. In general, the phenotypic manifestations of reciprocal duplications are milder and much more variable than those of the deletions. Of interest, non-penetrance, which we documented in two cases with duplication 16p13.3, has also been reported for several of these duplications (eg, dup 22q11.2, dup 15q11.2, ...).<sup>17–19</sup>

The defects observed in reciprocal deletion and duplication syndromes often involve the same organs or functions—for example, the heart in DiGeorge syndrome and duplication 22q11.2, speech in Williams–Beuren syndrome and duplication 7q11.23, the teeth in Smith–Magenis and Potocki–Lupski syndromes, or the nerves in Charcot–Marie–Tooth 1A and hereditary neuropathy with liability to pressure palsies.<sup>23–24</sup> Similarly, defects of the hands, feet and heart are seen in both deletion and duplication of 16p13.3.

In some instances, an intriguing reciprocal phenotype is seen in the deletion versus duplication. For example, 7q11.2 deletions have high verbal functioning, compared to particular deficiencies in speech and language development observed in the duplication 7q11.2.<sup>16</sup> The bulbous nasal tip observed in the present patients may perhaps be a reciprocal phenotype to the long columella seen in RTS, the short and proximally implanted thumbs may be reciprocal to the broad thumbs typical for RTS, and the arthrogryposis-like feature arguably compare to the joint hypermobility.<sup>25</sup>

The present findings indicate that normal *CREBBP* dosage is restricted not only by a lower threshold (as demonstrated in RTS) but also by an upper threshold. The described duplications most likely cause only a slight increase in *CREBBP* expression, with the normal genomic dose being only 33% lower than the dose upon duplication. This poses significant challenges to the recently proposed strategy to treat RTS patients with histone deacetylase inhibitors<sup>26</sup>: the dosage dependency of *CREBBP* suggests that such pharmaceutical interventions will prove beneficial in a very limited range of concentrations only. On the other hand, administering a precise dosage of histone acetyl transferase inhibitors such as curcumin<sup>27</sup> presents a valuable line of investigation to develop a therapy for the novel genomic disorder produced by *CREBBP* duplication. Curcumin is a cell permeable inhibitor of multiple cellular targets including *CREBBP* and p300 (a paralogue mutated in an allelic form of RTS), which is currently being tested in clinical trials for neoplastic and immunological disorders.<sup>28</sup> Although errors in development will not be curable by such strategies, the observed problems in mental function might benefit from this therapeutic intervention.

#### Author affiliations

<sup>1</sup>Center for Human Genetics, K.U. Leuven, Leuven, Belgium

<sup>2</sup>Service of Genetic Medicine, Geneva University Hospitals, Geneva, Switzerland

<sup>3</sup>Centre de Référence Anomalies du Développement et Syndromes Malformatifs PACA, Département de génétique médicale, Hôpital d'Enfants de la Timone, Marseille, France

<sup>4</sup>Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium

<sup>5</sup>Paediatric Neurology, Department of Paediatrics, Centre Hospitalier de Luxembourg, Luxembourg

<sup>6</sup>Departments of Pediatrics and of Medicine, University of Rochester, Rochester, New York, USA

<sup>7</sup>Department of Child Health, University of Missouri School of Medicine, Columbia, Missouri, USA

<sup>8</sup>Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital St. Louis, USA

<sup>9</sup>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada

<sup>10</sup>Medical Genetics Research Unit, Child and Family Research Institute, Children's and Women's Hospital, Vancouver, British Columbia, Canada

<sup>11</sup>Faculté de Médecine de La Timone, Université de la Méditerranée, Marseille, France

<sup>12</sup>Cytogenetic and Microarray Laboratories, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA

**Acknowledgements** The authors would like to express their sincere gratefulness to the patients and parents who agreed to participate in this study. BT is supported by an IWT specialisatiebeurs; JB is an aspirant FWO; NP is supported by PHRC 04-07; JMF's work was supported by a grant from Genome Canada. This work was made possible by grants from GOA/2006/12 and Center of Excellence SymbioSys (Research Council K.U.Leuven EF/05/007).

**Funding** Other funders: BT is supported by an IWT specialisatiebeurs; JB is an aspirant FWO; LV is supported by grants from Inserm and ANR Gis-Maladies Rares; NP is supported by PHRC 04-07; JMF's work was supported by a grant from Genome Canada. This work was made possible by grants from GOA/2006/12 and Center of Excellence SymbioSys (Research Council K.U.Leuven EF/05/007).

**Competing interests** None.

**Ethics approval** This study was conducted with the approval of the Etisch Committee K.U.Leuven, Belgium.

**Provenance and peer review** Not commissioned; externally peer reviewed.

#### REFERENCES

- Menten B, Maas N, Thienpont B, Buysse K, Vandesompele J, Melotte C, de Ravel T, Van Vooren S, Balikova I, Backx L, Janssens S, De Paepe A, De Moor B, Moreau Y, Marynen P, Fryns JP, Mortier G, Devriendt K, Speleers M, Vermeesch JR. Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. *J Med Genet* 2006;**43**:625–33.
- Slavotinek AM. Novel microdeletion syndromes detected by chromosome microarrays. *Hum Genet* 2008;**124**:1–17.
- Hennekam RC, Tilanus M, Hamel BC, Voshart-van Heeren H, Mariman EC, van Beersum SE, van den Boogaard MJ, Breuning MH. Deletion at chromosome 16p13.3 as a cause of Rubinstein–Taybi syndrome: clinical aspects. *Am J Hum Genet* 1993;**52**:255–62.
- Hannes FD, Sharp AJ, Mefford HC, de Ravel T, Ruivenkamp CA, Breuning MH, Fryns JP, Devriendt K, Van Buggenhout G, Vogels A, Stewart HH, Hennekam RC, Cooper GM, Regan R, Knight SJ, Eichler EE, Vermeesch JR. Recurrent reciprocal deletions and duplications of 16p13.11: the deletion is a risk factor for MR/MCA while the duplication may be a rare benign variant. *J Med Genet* 2008;**46**:223–32.
- Thienpont B, Breckpot J, Holvoet M, Vermeesch JR, Devriendt K. A microduplication of CBP in a patient with mental retardation and a congenital heart defect. *Am J Med Genet A* 2007;**143**:2160–4.
- Friedman JM, Baross A, Delaney AD, Ally A, Arbour L, Asano J, Bailey DK, Barber S, Birch P, Brown-John M, Cao M, Chan S, Charest DL, Farnoud N, Fernandes N, Flibotte S, Go A, Gibson WT, Holt RA, Jones SJ, Kennedy GC, Krzywinski M, Langlois S, Li H, McGillivray BC, Nayar T, Pugh TJ, Rajcan-Separovic E, Schein JE, Schnerch A, Siddiqui A, Van Allen MI, Wilson G, Yong SL, Zahir F, Eydoux P, Marra MA. Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation. *Am J Hum Genet* 2006;**79**:500–13.
- Marangi G, Leuzzi V, Orteschi D, Grimaldi ME, Lecce R, Neri G, Zollino M. Duplication of the Rubinstein–Taybi region on 16p13.3 is associated with a distinctive phenotype. *Am J Med Genet A* 2008;**146A**:2313–17.
- de Ravel T, Aerssens P, Vermeesch JR, Fryns JP. Trisomy of chromosome 16p13.3 due to an unbalanced insertional translocation into chromosome 22p13. *Eur J Med Genet* 2005;**48**:355–9.
- Rauch A, Hoyer J, Guth S, Zweier C, Kraus C, Becker C, Zenker M, Huffmeier U, Thiel C, Ruschendorf F, Nurnberg P, Reis A, Trautmann U. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. *Am J Med Genet A* 2006;**140**:2063–74.
- Gu W, Zhang F, Lupski JR. Mechanisms for human genomic rearrangements. *Pathogenesis* 2008;**1**:4.
- Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A, Robidoux F, Laflamme P, Cotterchio M, Greenwood C, Scherer SW, Zanke B, Hudson TJ, Bader GD, Gallinger

- S. Germ-line DNA copy number variation frequencies in a large North American population. *Hum Genet* 2007;**122**:345–53.
12. **Itsara A**, Cooper GM, Baker C, Girirajan S, Li J, Absher D, Krauss RM, Myers RM, Ridker PM, Chasman DI, Mefford H, Ying P, Nickerson DA, Eichler EE. Population analysis of large copy number variants and hotspots of human genetic disease. *Am J Hum Genet* 2009;**84**:148–61.
  13. **Redon R**, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, Gonzalez JR, Gratacos M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Armengol L, Conrad DF, Estivill X, Tyler-Smith C, Carter NP, Aburatani H, Lee C, Jones KW, Scherer SW, Hurles ME. Global variation in copy number in the human genome. *Nature* 2006;**444**:444–54.
  14. **Petrij F**, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, Breuning MH. Rubinstein–Taybi syndrome caused by mutations in the transcriptional co-activator CBP. *Nature* 1995;**376**:348–51.
  15. **Digilio MC**, Bernardini L, Capalbo A, Capolino R, Gagliardi MG, Marino B, Novelli A, Dallapiccola B. 16p subtelomeric duplication: a clinically recognizable syndrome. *Eur J Hum Genet* 2009.
  16. **Somerville MJ**, Mervis CB, Young EJ, Seo EJ, del Campo M, Bamforth S, Peregrine E, Loo W, Lilley M, Perez-Jurado LA, Morris CA, Scherer SW, Osborne LR. Severe expressive-language delay related to duplication of the Williams-Beuren locus. *N Engl J Med* 2005;**353**:1694–701.
  17. **Bolton PF**, Dennis NR, Browne CE, Thomas NS, Veltman MW, Thompson RJ, Jacobs P. The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. *Am J Med Genet* 2001;**105**:675–85.
  18. **Potocki L**, Bi W, Treadwell-Deering D, Carvalho CM, Eifert A, Friedman EM, Glaze D, Krull K, Lee JA, Lewis RA, Mendoza-Londono R, Robbins-Furman P, Shaw C, Shi X, Weissenberger G, Withers M, Yatsenko SA, Zackai EH, Stankiewicz P, Lupski JR. Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. *Am J Hum Genet* 2007;**80**:633–49.
  19. **Portnoi MF**. Microduplication 22q11.2: a new chromosomal syndrome. *Eur J Med Genet* 2009.
  20. **Ou Z**, Berg JS, Yonath H, Enciso VB, Miller DT, Picker J, Lenzi T, Keegan CE, Sutton VR, Belmont J, Chinault AC, Lupski JR, Cheung SW, Roeder E, Patel A. Microduplications of 22q11.2 are frequently inherited and are associated with variable phenotypes. *Genet Med* 2008;**10**:267–77.
  21. **Van Esch H**, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K, Lugtenberg D, Bienvenu T, Jensen LR, Gecz J, Moraine C, Marynen P, Fryns JP, Froyen G. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. *Am J Hum Genet* 2005;**77**:442–53.
  22. **Bi W**, Sapir T, Shchelochkov OA, Zhang F, Withers MA, Hunter JV, Levy T, Shinder V, Peiffer DA, Gunderson KL, Nezarati MM, Shotts VA, Amato SS, Savage SK, Harris DJ, Day-Salvatore DL, Horner M, Lu XY, Sahoo T, Yanagawa Y, Beaudet AL, Cheung SW, Martinez S, Lupski JR, Reiner O. Increased LIS1 expression affects human and mouse brain development. *Nat Genet* 2009;**41**:168–77.
  23. **Chance PF**, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B, Swanson PD, Odelberg SJ, Distèche CM, Bird TD. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. *Cell* 1993;**72**:143–51.
  24. **Lupski JR**, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, Chakravarti A, Patel PI. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. *Cell* 1991;**66**:219–32.
  25. **Hennekam RC**. Rubinstein–Taybi syndrome. *Eur J Hum Genet* 2006;**14**:981–5.
  26. **Kazantsev AG**, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. *Nat Rev Drug Discov* 2008;**7**:854–68.
  27. **Balasubramanyam K**, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. *J Biol Chem* 2004;**279**:51163–71.
  28. **Strimpakos AS**, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. *Antioxid Redox Signal* 2008;**10**:511–45.